摘要
近年来,随着针对程序性死亡受体1(programmed death 1,PD-1)及程序性死亡配体1(programmed death ligand 1,PD-L1)的免疫检查点抑制剂在中国获批的非小细胞肺癌适应证逐步增多,尤其是辅助免疫治疗及新辅助免疫治疗在临床实践中的不断应用,PD-L1免疫组织化学检测适用人群也随之有所变化。另外,国产PD-L1检测试剂也获批作为伴随诊断。因此,本共识在整合2020版国内PD-L1检测共识基础上,纳入近3年有关临床诊治进展内容,为适应并满足临床应用现状和需求,通过共识会议最终形成8条更新意见,旨在更好地指导非小细胞肺癌PD-1/PD-L1免疫检查点抑制剂临床应用中对PD-L1免疫组织化学表达检测的规范使用。随着后续更多研究与临床实践经验和数据的进一步积累,将会陆续进行相关内容的更新和完善。
作者
中国抗癌协会肿瘤病理专业委员会肺癌协作组、分子病理协作组
中国抗癌协会肺癌专业委员会
中国临床肿瘤学会非小细胞肺癌专业委员会
杨欣
袁培
林冬梅
应建明
陆舜
周彩存
Lung Cancer Study Group and Molecular Pathology Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association;Lung Cancer Professional Committee of Chinese Anti-Cancer Association;Expert Committee on Non-Small Cell Lung Cancer of Chinese Society of Clinical Oncology;Lin Dongmei;Ying Jianming;Lu Shun;Zhou Caicun(不详;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Department of Pathology,Peking University Cancer Hospital and Institute,Beijing 100142,China;Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Oncology,Shanghai Chest Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200030,China;Department of Medical Oncology,Shanghai Pulmonary Hospital,Cancer Institute,School of Medicine,Tongji University,Shanghai 200433,China)
出处
《中华病理学杂志》
CAS
CSCD
北大核心
2024年第2期121-129,共9页
Chinese Journal of Pathology
